Aspirin Articles
Aspirin may lower risk of melanoma, researchers suggest
11 March 2013
Clopidogrel with aspirin does not prevent more small strokes
5 February 2012
US FDA schedules advisory meeting VEGF Trap-Eye from Regeneron, Bayer; latter debuts Advanced Aspirin
25 May 2011
Australian Judge rules against Merck & Co’s Vioxx, saying the pain drug is not fit for sale
5 March 2010
Rarer Cancer Forum pleads with UK’s NICE to fund Bayer’s Nexavar
25 February 2010
Genzyme’s 4th quarter 2009 earnings plunge due to manufacturing problems for two leading products; expands research in Europe
18 February 2010
Uptake of the first oral MS therapies will result in the market value peaking at $8.4 billion in 2013
1 February 2010
Bayer says Ph II BAY79-4980 recombinant Factor VIII trial will not meet primary endpoint
25 January 2010
Sharp rise in US FDA approvals of biopharmaceuticals in 2009, highest since 2005, says BII
18 January 2010
US FDA warns four drugmakers on inaccurate promotion
13 January 2010
Does the MS market need another Interferon? US neurologists provide insight on the launch of Novartis’ Extavia
12 January 2010
New state pharma company - ENFARMA - created in Ecuador
4 January 2010
Bayer returns most rights to Recothrom to ZymoGenetics
22 December 2009
HRA Pharma expands to Spain and launches ellaOne
21 December 2009
Bayer Schering Pharma withdraws its MAA for Recothrom in Europe
16 December 2009
Atrial fibrillation drug market to grow more than sevenfold, to $6.1 billion in 2018
16 December 2009
European Commission confirms further surprise inspections in the pharmaceutical sector
10 December 2009
EU achieves political breakthrough on an enhanced patent system
8 December 2009
New anticoagulant studies may change current medical practice including use of aspirin and heparin in VTE and to prevent miscarriages
7 December 2009
Bristol-Myers Squibb and Pfizer to file apixaban In Europe; J&J unit submits palmitate for schizophrenia
7 December 2009
Venezuela to examine all pharma patents?
3 December 2009
UK Department of Health’s “money back” deal for MS drugs questioned; failing people with the disease
3 December 2009
Bayer Schering collaborates with Micromet on novel approach to cancer therapy in up to $429 million deal
2 December 2009
Regulatory approval briefs: Betaferon in China; new use for Lilly’s Cymbalta in USA; update on telavancin
1 December 2009
Venezuela invalidates two Bayer moxifloxacin patents
30 November 2009
EU Commission and pharma industry launch second call for research proposal towards more efficient drug development methods
30 November 2009
Big Pharma seeks to insulate itself from impact of ‘patent cliff’
24 November 2009
UK’s NICE again rejects Bayer’s Nexavar for advanced liver cancer, but company can, and will, appeal
19 November 2009
AstraZeneca presents strong Ph II results for Brilinta at AHA, beating Plavix; files drug with FDA
19 November 2009
MEPs and EU pharma industry debate commitment to deliver 21st Century health care systems in times of crisis
5 November 2009
UK’s NICE backs GSK’s Hycamtin for cervical cancer and Lilly’s Efient for preventing blood clots
28 October 2009
Batch of approvals and positive opinions from EU’s CHMP
26 October 2009
Animal research deserves defending
22 October 2009
Third-quarter 2009 profit sinks at Genzyme, on production woes
22 October 2009
Four drugmakers to pay $124 million for submission of false claims to USA’s Medicaid
20 October 2009
“No Frills Drugs” push Pharma to look for a cure
30 September 2009
Bayer’s regorafenib shows promise in renal cancer, may fuel Onyx dispute
22 September 2009
Arthur Higgins to quit as CEO of Bayer Healthcare; Marijin Dekkers to be Bayer group CEO
16 September 2009
Changes predicted in renal cell carcinoma market leaders
15 September 2009
Innovative medicines initiative: putting Europe at the forefront of biopharmaceutical innovation
15 September 2009
GW reveals strong Sativex data in multiple sclerosis
14 September 2009
Public Citizen’s HRG slams Pfizer’s $2.3 billion settlement as not enough to deter bad behaviour by Pharma
9 September 2009
UK’s NICE again refuses Nexavar for liver cancer patients
8 September 2009
Bayer completes Ph II rivaroxaban study enrollment
1 September 2009
China publishes Essential Drugs list of 307 products
25 August 2009
Bayer submits new Levitra formulation in EU
19 August 2009
Novartis Multiple sclerosis drug Extavia cleared by US FDA
17 August 2009
US FDA clears new formulation of Actelion’s Ventavis
10 August 2009
Japan stock market week to June 8, 2009
9 June 2009
Bionovo names Klaus Kohl CTO
4 June 2009
Stock Commentary - Europe - week to June 1, 2009
4 June 2009
Bayer reports further riociguat data at ATS
3 June 2009
Onyx/Bayer initiate Ph III Nexavar trial
3 June 2009
FDA does not ask for new rivaroxaban trials
3 June 2009
Fresenius licenses HES platform to Bayer
2 June 2009
Japan: no added use for Nexavar, Alimta
27 May 2009
Bayer/Onyx
21 May 2009
US FDA approves Impax' generic Precose
20 May 2009
Onyx asserts right to Ph II drug against Bayer
19 May 2009
246M euros for EC/EFPIA's IMI drug R&D project
19 May 2009
Bayer begins European roll-out of Qlaira
14 May 2009
Xarelto more effective than enoxaparin in VTE
11 May 2009
Evotec buys Sumit Zebrafish operations
8 May 2009
AstraZeneca files for aspirin/esomeprazole
5 May 2009
Bayer debuts first TV ad for Levonelle in UK
29 April 2009
NICE's "bizarre" decision
29 April 2009
Bayer licenses Ardea's MEKs for up to $407M
29 April 2009
Bayer hit by charges and falling material science sales in 1st qtr, but pharma division doing well
29 April 2009
Research links early aspirin use to cancer prevention
28 April 2009
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
